Moderna, Inc. (ETR:0QF)
Market Cap | 9.25B |
Revenue (ttm) | 2.62B |
Net Income (ttm) | -2.47B |
Shares Out | n/a |
EPS (ttm) | -6.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,185 |
Average Volume | 992 |
Open | 26.14 |
Previous Close | 26.44 |
Day's Range | 23.28 - 26.54 |
52-Week Range | 20.18 - 110.94 |
Beta | 1.85 |
RSI | 38.56 |
Earnings Date | Jul 31, 2025 |
About Instructure Holdings
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsNews

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.This decision affirms the ...

UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the...

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1.

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Moderna, Inc. (NASDAQ: MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1 . Analysts expect the Cambridge, Massachusetts-based company to report qua...
Moderna braces for deep Q2 loss as vaccine demand wanes

Moderna's Earnings: A Preview
Moderna (NASDAQ: MRNA) is preparing to release its quarterly earnings on Friday, 2025-08-01. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Mod...
Moderna gets EU nod for updated COVID-19 vaccine
More than 800 Moderna employees will lose their jobs this year as costs are slashed
Moderna announced a large layoff the day before the vaccine maker was set to release second-quarter results.
5 stocks to watch on Thursday: FIG, ABBV, MRNA, AMZN, AAPL
Moderna to lay off 10% of staff this year

Moderna to cut 10% of global workforce as Covid shot sales drop 20%
Moderna is reducing its global workforce by around 10% by the end of 2025 as demand for Covid-19 vaccines continues to weaken. The company, which had about 5,800 full-time employees across 18 countrie...

Moderna plans to lay off 10% of workforce to cut costs
Moderna plans to trim roughly 10% of its global workforce by the end of the year to cut costs amid declining sales of its COVID-19 vaccines, the company said on Thursday.

Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of the year.

Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C...

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C...

Moderna Announces Data to be Presented at ESMO Congress 2025
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2...

Moderna Announces Data to be Presented at ESMO Congress 2025
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2...

Down 74% Over the Past Year, Is Moderna Stock a Buy?
Market Whales and Their Recent Bets on MRNA Options
Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna (NASDAQ: MRNA) we detected 9 trades. If we consider the specifics of eac...

EU regulator backs Moderna's updated COVID vaccine
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / M...

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / M...

What's Going On With Moderna Stock Wednesday?
Moderna Inc.’s (NASDAQ: MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date. On Wednesday, the stock is trading around 7% higher. Notably, there is no ne...